<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2252">
  <stage>Registered</stage>
  <submitdate>10/02/2009</submitdate>
  <approvaldate>10/02/2009</approvaldate>
  <nctid>NCT00841217</nctid>
  <trial_identification>
    <studytitle>Regulation of Lipoprotein Transport in Metabolic Syndrome</studytitle>
    <scientifictitle>Effect of PPAR-Delta Agonist on Lipoprotein Kinetics in Metabolic Syndrome</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>UWA_PHR022009</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obesity</healthcondition>
    <healthcondition>Lipid Disorders</healthcondition>
    <healthcondition>Cardiovascular Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - GW501516
Treatment: drugs - placebo pill

Placebo Comparator: 1 - placebo group

Active Comparator: 2 - GW501516, 2.5mg


Treatment: drugs: GW501516
2.5mg/day

Treatment: drugs: placebo pill


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>ApoB transport rate</outcome>
      <timepoint>5 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>ApoA and C-III transport rate</outcome>
      <timepoint>5 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Any three of the following:

               -  Waist circumference &gt; 102 cm

               -  Triglycerides &gt; 150 mg/dL

               -  HDL-cholesterol &lt; 40 mg/dL

               -  Blood glucose &gt; 110 mhg/dL

               -  Blood pressures &gt; 130/85 mmHg</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Triglycerides &gt; 500 mg/dL

          -  Diabetes mellitus

          -  CVD

          -  Consumption of &gt; 30 g alcohol/day

          -  Use of agents affecting lipid metabolism

          -  APOE2/E2 genotype

          -  Creatinemia (&gt; 120 umol/L)

          -  Hypothyroidism

          -  Abnormal liver and muscle enzymes</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>13</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>University of Western Australia - Perth</hospital>
    <postcode>6000 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The University of Western Australia</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>National Heart Foundation, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether PPAR-delta agonist (GW5015156)had favorable
      effect on lipoprotein metabolism.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00841217</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>